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TO EVALUATE THE SAFETY AND EFFICACY OF INTRA-ARTICULAR 
TRANEXAMIC ACID IN PRIMARY TOTAL JOINT ARTHROPLASTY 
JOSEPH PARK 
ABSTRACT 
Background: Tranexamic acid (TXA) has become highly utilized in total joint 
arthroplasties for its anti-fibrinolytic effect. Recently, intra-articular application of TXA 
has become popular for its avoidance of systemic distribution within the body. With a 
more direct application to the surgical site, there is interest to see if topical application 
will provide hemostasis without increasing rates of venous or arterial thrombotic events 
and infections. In particular, there is lack of published data describing the safety of TXA 
in patients who have a significant disposition towards thromboembolic events. 
Methods: This study was a retrospective chart-review (RCR) to assess the safety and 
efficacy of intra-articular TXA (IA-TXA) in total knee and hip arthroplasty patients. IA-
TXA 2g/50mL NS was administered to patients who were contraindicated for IV-TXA 
usage based on our hospital’s guidelines (history of VTE events, mitral or aortic valve 
replacement with additional risk factors for stroke, active cancer, genetic or acquired 
thrombophilia, significant cardiac disease, serum creatinine > 2.8 mg/dL). Primary 
efficacy outcomes were total blood loss on post-operative day 1 (POD1), overall 
perioperative blood loss, and changes in hemoglobin/hematocrit values over the hospital 
stay. Primary safety outcomes were the incidence of arterial or venous thrombosis and 
wound infections. The study compared patients who received IA-TXA (study group) to 
patients who did not receive TXA (control group). The study included TKA patients=156 
  vi 
(Control=72 Study=83), anterior THA patients=57 (Control=20 Study=37), and posterior 
THA patients=59 (Control=27 Study=32). 
Results: TKA patients administered IA-TXA showed a significant decrease in POD1 
blood loss compared to the control group [305.84 mL, p = 0.004]. Additionally, the 
control patients showed significantly lower levels of overall hematocrit than those who 
had received IA-TXA [0.9 units, p = 0.041]. However, IA-TXA did not cause a reduction 
in blood loss in either the anterior or posterior THA patients. No statistically significant 
differences existed between treatment and control groups for transfusion rates or post-
operative complications (VTE events and infections).    
Conclusion: IA-TXA 2g/50mL is effective in reducing blood loss in TKA patients; 
however, further research is needed regarding IA-TXA use in THA patients. The lack of 
efficacy in THA may have been related to the dosage used, the volume instilled, the 
timing of administration, or technique of administration.   
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INTRODUCTION 
  
Total joint arthroplasty (TJA) is becoming increasingly more common in the 
United States, with over 450,000 patients having undergone a total hip arthroplasty 
(THA) and 720,000 patients having undergone a total knee arthroplasty (TKA) in 2010 
(Wong et. al., 2010). These procedures are also touted to be one of the most successful 
orthopedic surgical interventions performed to date (Huang, et. al., 2017). With an aging 
population and a health care system that incentivizes good outcomes, it has become even 
more imperative that total joint arthroplasty become more streamlined with evidence 
based, multi-modal therapies. One significant issue that is diminished by the 
implementation of such a strategy is perioperative blood loss.  
 Blood loss from TJA is common and large, with blood loss from THA, averaging 
between 700 mL to 2000 mL, and from TKA, averaging between 1450 mL to 1790 mL 
(Georgiev et. al, 2018) (Wong et. al, 2010). Such a large amount of blood loss has given 
way to postoperative anemia in many of these patients (Wong et. al, 2010). In response, 
use of transfusions after TJA has increased, with 11 to 67% of THA patients and 4 to 
64% of TKA patients undergoing a blood transfusion (Georgiev et. al, 2018) (Abdel et. 
al, 2018). However, use of transfusion is not without its own risks including the 
transmission of blood-borne pathogens, auto-immune reactions, and circulatory overload 
(Abdel, 2018). A major cause of perioperative blood loss following TKA and THA is 
increased fibrinolysis stimulated by surgical trauma and release of the tourniquet (in 
TKA) (Rong et. al, 2013). The use of anti-fibrinolytic agents, such as aminocaproic acid 
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and tranexamic acid (TXA), has offered alternative methods to diminish perioperative 
blood loss by minimizing the fibrinolysis in the first place (Nilsson, 1980).  
  
Anti-fibrinolytic compounds (Aminocaproic Acid and Tranexamic Acid) 
 Aminocaproic acid was first discovered by Japanese scientists in a search for 
clinically-relevant anti-fibrinolytic compounds (Nilsson, 1980). With a mechanism of 
action described as inhibiting plasmin activation and with oral formulations that produced 
no toxicity in humans, aminocaproic acid was a giant step forward for utilizing anti-
fibrinolytic compounds in humans (Nilsson, 1980). Later on, the same scientists 
discovered a more potent compound: tranexamic acid. In fact, TXA was found to be 6-10 
times more active than aminocaproic acid (Nilsson, 1980).  
 TXA is a synthetic analog of the amino acid lysine that causes anti-fibrinolytic 
activity when it competitively, and non-competitively at higher concentrations, binds to 
the lysine-binding sites of plasminogen (Rong et. al, 2013) (Pfizer Inc., 2017). These 
lysine-binding sites are used to bind activated plasminogen, or plasmin, to the fibrin clot 
in order to induce fibrinolysis. Therefore, although plasminogen is activated by tissue 
plasminogen activator (t-Pa) into plasmin, it is unable to bind to fibrin, hindering its 
fibrinolytic activity (Georgiev et. al, 2018). This mechanism is depicted in Figure 1 
(Hoffman, et. al, 2016).  
While the body naturally responds to and inhibits fibrinolysis after 24 hours, the 
administration of TXA beforehand allows for a much earlier inhibition of this process 
(Rajesparan et. al, 2009). Specifically, this is possible through in-activation of 
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plasminogen before it binds to the fibrin clot. In fact, 80% reduction of plasminogen 
activity is required for the fibrinolytic cascade to be suppressed (Rajesparan et. al, 2009).  
 
 
Figure 1. TXA mechanism of action. In this simplified model, the physiologic breakdown of fibrin via 
activated plasmin is shown on the left, whereas the pharmacologic effect of TXA on fibrinolysis is shown 
on the right (Hoffman, et. al, 2016). 
 
It has been shown that TXA (administered intravenously) is highly distributed 
throughout the entire body, including the fluid and synovial membrane of the joints 
(Nilsson, 1980). TXA is mainly eliminated by the kidneys via glomerular filtration. 
When TXA is infused at 10 mg/kg, 30% of TXA is excreted in the urine within 1 hour of 
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administration, and 90% of TXA is excreted in urine within 24 hours of administration 
(Nilsson, 1980). Any kidney pathology would lead to a delay in TXA clearance, and 
therefore would prolong the half-life of the active compound (Nilsson, 1980). 
Administration must therefore be corrected for patients with kidney disease.  
TXA’s effective anti-fibrinolytic activity reached across many disciplines, 
including orthopedic surgery. While TXA is utilized across multiple fields in preventing 
excessive bleeding, the only FDA approved indications are for use in hemophiliacs 
undergoing dental procedures, and in women with idiopathic menorrhagia (Pfizer Inc., 
2017). The first study to ever describe TXA’s efficacy in reducing blood loss after THA 
was published in 1995 (Benoni, et. al, 2018). Ever since, many studies have reported and 
described TXA’s safety and efficacy profile in TJA (Georgiev, 2018). A bulk of the 
literature regarding TXA’s use in TJA involves the intravenous administration of TXA 
(IV-TXA).  
  
Intravenous Tranexamic Acid 
In 2009, Rajesparan et. al studied the efficacy of IV-TXA given during THA. The 
data analyzed was collected from a previous randomized, double-blind study that 
compared various VTE prophylaxis agents. Specifically, a subset of these patients was 
assessed where half received IV-TXA and the other half did not receive TXA. Early and 
late changes in hemoglobin and hematocrit were measured such that early changes ranged 
from pre-operatively to the night of surgery, and late changes ranged from the night of 
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surgery to POD 6. Blood loss was approximated through the use of the Gross formula 
which utilizes perioperative hematocrit values (Gross, 1983). 
The analysis of this subset of patients showed that while intraoperative blood loss 
was not affected by administration of IV-TXA, both early reductions in 
hemoglobin/hematocrit and total blood loss significantly decreased when IV-TXA was 
administered. In addition, there was a significantly lower number of patients who 
required transfusions in the IV-TXA group compared to those in the control group (3 
patients in IV-TXA group vs. 10 patients in control group); however, the actual number 
of units transfused did not differ significantly between treatment and control groups (21 
units in control group vs. 6 units in TXA group). Finally, the safety of IV-TXA 
administration was highlighted as the number of VTE events did not increase with IV-
TXA administration (Rajesparan et. al, 2009).  
In 2017, Krauss et. al. conducted a retrospective cohort study to determine 
whether IV-TXA can decrease postoperative blood loss after THA and TKA. A 
secondary endpoint was to determine if IV-TXA can improve the likelihood of patients 
ambulating earlier after surgery. The study was constructed to compare THA or TKA 
patients who were administered IV-TXA to those who received no TXA. Daily 
hematocrit/hemoglobin levels and the use of post-operative transfusions were measured 
in order to compare post-operative blood loss. Intra-operative blood loss was measured 
by the anesthesiologist by subtracting any saline irrigation volume from the total volume 
in the suction canister. Early ambulation was measured through the patient’s daily 
distance walked in feet.  
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The results showed IV-TXA use decreased the level of hemoglobin and 
hematocrit lost post-operatively. This reduction in hemoglobin and hematocrit loss 
correlated with improvements in early ambulation. This was significant as early 
ambulation is a known indicator of favorable outcomes from TJA. Additionally, use of 
IV-TXA led to a decrease in the number of patients requiring a transfusion compared to 
patients that were not given TXA [1.64% vs. 17.12%, respectively; P < .0001] (Krauss, 
2017). Relevant results of this study are shown in Table 1 below. 
 IV-TXA No TXA P 
THA – anterior    
Hemoglobin (g/dL) 10.57 9.64 .0009 
Hematocrit (%) 31.58 28.61 .0004 
Ambulation (feet) 27.24 13.19 <.0001 
THA – posterior    
Hemoglobin 11.04 10.16 .0003 
Hematocrit 32.93 30.17 <.0001 
Ambulation 24.68 12.93 <.0002 
TKA    
Hemoglobin 11.02 10.11 <.0001 
Hematocrit 33.01 30.20 <.0001 
Ambulation 25.81 18.75 .0054 
 
Table 1. Changes in Hemoglobin, Hematocrit, & Ambulation: Compares the mean hemoglobin, 
hematocrit, and distance walked on POD 2 between the IV-TXA and No-TXA groups. P-values < .05 were 
considered statistically significant (Krauss, 2017). 
As referenced by the above studies, it is evident that IV-TXA use significantly 
decreases perioperative bleeding, decreases use of blood transfusions, and increases the 
likelihood of favorable outcomes after TJA (Krauss, et. al, 2017) (Rajesparan et. al, 
2009). However, in the face of these benefits, clinicians still have concerns regarding IV-
TXA use due to its rapid and widespread distribution within the body. It is feared that the 
systemic distribution of TXA may lead to an increased disposition towards abnormal 
clotting and venous thromboembolism (VTE) (Abdel et. al., 2018). Therefore, interest in 
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alternative applications of TXA has grown substantially, particularly in the intra-articular 
application of TXA (IA-TXA). 
 
Intra-articular Tranexamic Acid 
IA-TXA use involves pouring the diluted solution of TXA with normal saline into 
the joint prior to the closing of the incision (Abdel et. al., 2018). In regards to safety, 
pharmacologic studies in rabbits have shown lower peak plasma concentrations of TXA 
after IA-TXA administration compared to after IV-TXA administration [Cmax: 
30.65±3.31 µg/mL vs. 54.05±6.21 µg/mL, respectively; p < 0.01] (Rong et. al, 2013). In 
fact, in a clinical trial comparing different doses of IA-TXA in TKA patients, Wong et. al 
(2010) showed that IA administration of TXA produced a 70% decrease in peak plasma 
levels compared to that produced by an equivalent dose of IV-TXA. Therefore, IA-TXA 
has been favored as the safer administration between the two, particularly in patients with 
a significant disposition towards having future VTE events.   
In regards to efficacy, there are a multitude of studies that have shown IA-TXA to 
significantly decrease perioperative blood loss and transfusion use in both TKA and THA 
without increasing the rates complications (including VTE and infections) after surgery 
(Wong, et. al, 2010) (Yue, et. al, 2014) (Fillingham, et. al, 2018). In addition, the same 
pharmacologic study in rabbits mentioned beforehand showed that IA-TXA 
administration reaches a prolonged therapeutic drug level compared to that of IV-TXA 
administration (Rong et. al, 2013). Multiple clinical studies confirm both the efficacy and 
safety of IA-TXA: 
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 In 2010, Wong et. al conducted a study to compare various dosages of IA-TXA in 
TKA patients. The study split patients into 3 groupings of TXA dosages: 1.5-g IA-TXA, 
3-g IA-TXA, and a placebo group. Postoperative blood loss was significantly reduced in 
both 1.5 g and 3 g TXA groups compared to the placebo group [p = 0.017]. Specifically, 
patients that were administered IA-TXA had 20% to 25% less bleeding than patients who 
did not receive TXA; however, the difference was minimal between the groups that were 
administered different dosages (1.5 g TXA: 1295 mL; 3.0 g TXA: 1208 mL; Placebo: 
1610 mL). In addition, patients in the TXA group had 16 to 17% greater levels of 
hemoglobin than the control (placebo) group [p < 0.008] (Wong et. al, 2010). 
 In 2014, Yue et. al conducted a prospective study looking at the efficacy and 
safety of 3 g of IA-TXA in THA patients. Their results showed that 3 g of IA-TXA can 
significantly decrease the use of transfusions from 22.4% to 5.7% without increasing the 
incidence of VTE events or other postoperative complications [p = 0.021]. In addition, 
the use of IA-TXA in THA patients caused a significant reduction in total blood loss 
(approximately 300 mL) and decrease in hemoglobin/hematocrit levels as compared to 
that of the control group [p < 0.001] (Yue et. al, 2014). 
 Although a significant level of efficacy has been shown for TXA and it’s different 
administrations, there is currently a lack of high-level evidence supporting use of TXA in 
higher-risk patients defined as a history of venous-thromboembolism (VTE), myocardial 
infarction (MI), cerebrovascular accident (CVA), trans-ischemic attack (TIA), and/or 
vascular stent placement (Fillingham et. al, 2018). This is mainly due to the fact that 
these patient populations are being excluded from TXA studies for fear of inducing a pro-
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coagulatory state. For example, Wong et. al (2010), in their randomized control trial 
comparing various dosages of IA-TXA in TKA patients, excluded patients who had, 
amongst other factors, a history of arterial or venous thromboembolism, MI, or CVA.  
While there are a dearth of studies involving higher-risk patients, the theory 
behind the mechanism of action for TXA involves stabilizing clots that have already been 
formed, rather than creating a clot-promoting state (Rajesparan, et. al, 2009). In fact, 
Dastrup et. al recently published the results of a study that utilized data from the Danish 
national registry showing that intraoperative administration of TXA in THA does not 
increase the risk for any cardiovascular event or death following the surgery (Dastrup et. 
al, 2018). The dosage and administration of TXA were not recorded in this study; 
however, the authors have stated that IA-TXA was not highly utilized in Denmark at the 
time of data collection (Dastrup et. al, 2018). 
 
Accurate Measurements of Perioperative Blood Loss 
In order to determine efficacy and allow for inter-study comparison, it is 
imperative that blood loss be measured with a standardized and accurate method; 
however, there is no clear consensus as to a standard method for estimating blood loss. 
Currently, there does appear to be some consensus as to measuring visible blood loss 
intraoperatively and postoperatively through the collection of intra-operative drainage 
and bloody surgical pads; however, these methods do not provide an accurate 
measurement of blood loss, and do not take into account the large volume of blood that 
may be retained in tissue (Lopez-Picado et. al, 2017). In fact, Eipe & Ponniah showed the 
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use of such clinical methods underestimated surgical blood loss by 64% (Eipe & Ponniah, 
2006). Effort has been made to develop alternative formulas that can be used to estimate 
the total blood loss (EBL) which includes both visible and hidden blood loss (Lopez-
Picado et. al, 2017) (Eipe & Ponniah, 2006) (Sehat & Newman, 2000) (Gross, 1983).  
These formulas utilize an estimated blood volume (EBV) and a comparison of 
preoperative to postoperative hematocrit or hemoglobin changes. For example, the Gross 
formula estimates blood loss as a fraction of the estimated blood volume based on 
Moore’s formula (taking into account the patient’s gender, weight in kilograms, and body 
build by BMI) (Lopez-Picado et. al, 2017). The fraction of blood loss is determined by 
the difference between the preoperative hematocrit (initial) and the lowest hematocrit 
(final) divided over the average of these two values (Lopez-Picado et. al, 2017). 
𝐆𝐫𝐨𝐬𝐬 𝐅𝐨𝐫𝐦𝐮𝐥𝐚: 𝐸𝐵𝐿 = 𝐸𝐵𝑉 × (
 𝑃𝑟𝑒𝑜𝑝 𝐻𝑐𝑡 −  𝐿𝑜𝑤𝑒𝑠𝑡 𝑃𝑜𝑠𝑡𝑜𝑝 𝐻𝑐𝑡 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐻𝑐𝑡
) 
This is a derivation of a simple linear formula, which contains only the initial hematocrit 
in the denominator. By adjusting to an average hematocrit, any gain or loss to the blood 
volume, and therefore hematocrit, is accounted for (Gross, 1983).    
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SPECIFIC AIMS 
 
Hypothesis: In patients undergoing a primary total hip or knee arthroplasty, the 
administration of IA-TXA provides superior hemostasis compared to no administration of 
IA-TXA. Additionally, IA-TXA will not increase the rate of thromboembolic events or 
infection in these patients. 
 
Primary Objectives: 
1. To assess if TKA and THA patients that have been administered IA-TXA (study 
group) have a reduction in perioperative blood loss compared to patients who 
have not been administered TXA (control group) 
 
Secondary Objectives:  
1. To assess if there is a reduction in hospital length of stay (LOS) in TKA and THA 
patients administered IA-TXA (study group) compared to patients who have not 
received TXA (control group)  
2. To assess the safety profile of IA-TXA in primary TKA and THA patients by 
measuring postoperative VTE and infection rates  
 12 
 METHODS 
 
Patients   
In August 2016, this retrospective cohort study received Institutional Review 
Board approval to evaluate the safety and efficacy of IA-TXA in patients who underwent 
a primary TKA, primary anterior THA, or primary posterior THA. The study group 
(administered IA-TXA) included patients undergoing these procedures from April 2016 
to April 2017. This was when IA-TXA use was introduced in the hospital. The control 
group (not administered any TXA) included patients undergoing these procedures from 
September 2014 to September 2015.1  
 All adult patients (patients over the age of eighteen years) who were scheduled for 
a unilateral primary TKA or THA at Northwell Syosset Hospital were eligible for 
inclusion in this study. Exclusion criteria included patients who were unwilling to 
undergo blood transfusion, if necessary, received IV-TXA intraoperatively, had not 
received IA-TXA for 5 minutes as per protocol, had an allergy to TXA, were receiving 
erythropoietin therapy for anemia, or had received blood transfusion within 30 days of 
surgery.  
 
Surgical Technique 
 All total knee and hip arthroplasties were performed amongst ten orthopedic  
1 IA-TXA was first introduced in October 2015 for use in our hospital. This began a transition period until 
March 2016, where our surgeons adjusted to using IA-TXA in their cases (change in the volume of 
administration: 100 mL to current 50 mL). No patients from this time were included for review. 
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The choice in performing a posterior versus an anterior hip arthroplasty was based on 
surgeon preferences. Due to the differences that existed between each of these surgeries, 
the three surgery types (TKA, anterior THA, posterior THA) were considered and 
analyzed independently from each other. Perioperative care was guided by departmental 
protocols based on extensive literature review, including the management of 
perioperative blood loss with TXA. Specifically, departmental guidelines were updated to 
manage IA-TXA use for those patients undergoing TKA and THA who were found to 
have contraindications for receiving IV-TXA. In regards to anesthesia, a majority of the 
patients were administered a single shot spinal anesthetic; otherwise, patients were given 
general anesthesia if contraindicated for a spinal anesthetic. In addition, TKA patients 
were typically administered an adductor or femoral canal block by the anesthesiologist 
for further postoperative pain relief. No significant differences existed in the 
perioperative management between the treatment and control groups. 
 In both TKA and THA cases, the operative joint was irrigated with 2 grams of 
TXA in 50 mL of Normal Saline using a bulb syringe after cementing the final 
components. The irrigation fluid was left undisturbed for 5 minutes. Any excess solution 
was irrigated out of the surgical site by placing the suction tip on the cemented 
component without touching the joint or the surrounding tissue surfaces [Appendix 1]. In 
TKA cases, the tourniquet was then released (held at 350 mmHg during the procedure) 
and any bleeding from superficial vessels was controlled with electrocautery. Drains were 
inserted at the discretion of each surgeon for both TKA and THA cases. 
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Perioperative Management 
The blood transfusion protocol was consistent for all the postoperative patients 
being evaluated. Patients received allogeneic blood transfusions when the hemoglobin 
was less than or equal to 7 g/dL. Patients with a hemoglobin greater than 7 g/dL but less 
than 8 g/dL were treated only if they exhibited clinical symptoms related to anemia or if 
there was a rapid decline in hemoglobin. Patients with a hemoglobin greater than or equal 
to 8 g/dL were treated only if they exhibited clinical symptoms of anemia. 
 Postoperative venous thromboembolic chemoprophylaxis following TKA and 
THA was based on departmental risk stratification into low (Aspirin) or high (Lovenox, 
Eliquis, or Aspirin) risk for VTE. This took into account any past VTE events within the 
prior year, active malignancy, morbid obesity (BMI greater than or equal to 40), and a 
history of inherited or acquired thrombophilia(s). Patients on anticoagulant therapy 
preoperatively were interrupted in their therapy before surgery and resumed their therapy 
again on POD 2. These patients were administered VTE prophylaxis on POD 1 based on 
departmental guidelines. In addition, surgeon preferences were ultimately involved in 
choosing a certain drug for VTE chemoprophylaxis. Chemoprophylaxis was started on 
POD 1 [Appendix 2].  
Mechanical prophylaxis for VTE was also utilized via compression stockings put 
on the patients before they left the operating room. Early ambulation was initiated by 
physical therapists within 4 hours of arrival to the post-operative recovery unit, with a 
medical contraindication being the only reason for not ambulating. 
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Outcome Measures    
The primary study outcome was measured through the total estimated blood loss 
before and after administration of VTE chemoprophylaxis. Estimated blood loss (EBL) 
was calculated using the Gross Formula: 𝐸𝐵𝐿 = 𝐸𝐵𝑉 × (
𝑃𝑟𝑒𝑜𝑝 𝐻𝑐𝑡 − 𝐿𝑜𝑤𝑒𝑠𝑡 𝑃𝑜𝑠𝑡𝑜𝑝 𝐻𝑐𝑡
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐻𝑐𝑡
). 
This approach takes into account the estimated blood volume (EBV) according to weight 
in kilograms and body habitus (obese, normal, thin, muscular), the average hematocrit, 
and the difference between the lowest hematocrit during hospitalization and the pre-
operative hematocrit (Gross, 1983). EBL was calculated at two different time points in 
order to isolate the effect of anticoagulation on bleeding: before VTE chemoprophylaxis 
administration (using HCT value from POD1) and after VTE chemoprophylaxis 
administration (using lowest HCT value from all PODs). 
This method was used to provide a more standardized method of calculating 
blood loss. As mentioned previously, assessment of blood loss through clinical methods 
such as weighing blood-soaked sponges and quantifying blood lost through drainage 
underestimates surgical blood loss by as much as 64% (Eipe and Ponniah, 2006). 
Perioperative blood loss in the study was also measured through the difference between 
the preoperative hematocrit/hemoglobin and the lowest hematocrit/hemoglobin recorded 
in the patient’s hospital stay (values recorded once per post-operative day).  
Secondary study outcomes were measured by the number of allogeneic blood 
transfusions given during hospitalization, thromboembolic events occurring within 30 
days of surgery, and surgical site infections occurring within 90 days of surgery. 
Specifically, patients were screened for VTEs only if they presented with relevant 
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symptoms (i.e. calf pain, shortness of breath, non-postoperative swelling, fever). The 
presence of an infection was determined by the physician’s assistant, nurse practitioner, 
or surgeon who examined the patient in the outpatient post-operative visit. 
Other objective clinical measurements captured included preoperative platelet 
count, postoperative platelet count (once for each post-operative day), American Society 
of Anesthesiologists (ASA) classification, length of procedure in minutes (from first 
incision to incision closure), postoperative thromboembolic chemoprophylaxis agent 
used, and length of hospital stay (LOS). Patient demographics and characteristics were 
also captured including age, gender, significant comorbidities, weight, height, BMI, 
specific procedure performed (TKA, anterior THA, posterior THA), surgeon, date of 
surgery, and disposition after discharge (either home or rehabilitation center). 
  
Statistical Analysis 
 Descriptive statistics were calculated for all variables that were collected. 
Specifically, categorical variables were described with frequency distribution and 
percentage breakdowns. Continuous variables were described with means, standard 
deviations, medians, interquartile ranges, maximums, and minimums.  
 A Wilcoxon Rank Sum test was used to determine whether there was a difference 
in patient demographics (including age at surgery, body height and weight, BMI), the 
time between surgery and discharge, and the duration of surgery between the control and 
treatment groups. 
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 A Chi-square or Fisher’s Exact test were used to determine whether there was a 
difference in the distribution of patients who received IA-TXA treatment by gender, type 
of anesthesia administered, ASA score, type of surgery, transfusion status (whether the 
patient requires a transfusion), presence of post-operative thromboembolic events, or 
presence of a surgical site infection within 90 days post-operatively between the control 
and treatment groups. 
A linear mixed model was used to model perioperative blood loss as a function of 
group (IA-TXA and control), procedure type (TKR, anterior THR, and posterior THR) 
and potential confounders (i.e. type of anesthesia administered, gender, age). A mixed 
models approach was used to account for the clustered (i.e. hierarchical) nature of the 
data; namely, multiple subjects within a surgeon.   
For all longitudinal outcomes, such as hemoglobin and hematocrit, linear mixed 
models for repeated measures were used to compare outcomes between groups, 
procedure type, as well as changes in outcomes over time. Interactions between group, 
procedure, and time were explored.  Potential confounders were also included in the 
model.   
The above analyses were repeated separately for knee replacement and hip 
arthroplasty subjects. 
Statistical Analysis Software (SAS) v. 9.4 was used for analysis. This version was 
originally released on July 2013 and produced by the SAS Institute.   
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RESULTS 
 
Patient Demographics and Clinical Characteristics 
 A total of 271 patients were analyzed in this retrospective chart review. 152 
patients received IA-TXA (56%) (April 2016 to April 2017), while 119 patients did not 
receive TXA (44%) (September 2014 to September 2015). Within the IA-TXA group, 37 
patients had an anterior THA, 32 patients had a posterior THA, and 83 patients had a 
TKA. Within the control (no-TXA) group, 20 patients had an anterior THA, 27 patients 
had a posterior THA, and 72 patients had a TKA. There were no statistically significant 
differences in age (in years) [p = 0.4259], height (in cm) [p = 0.1929], weight (in kg) [p = 
0.0813], BMI [p = 0.1322], gender [p = 0.1572], or length of stay (in days) [p = 0.1242] 
between the IA-TXA group and the control group. A majority of patients were classified 
as ASA III (84%), and received Spinal/Epidural anesthesia (64%). There was no 
difference in the distribution of patients receiving a certain type of anesthesia, or being 
classified as a certain ASA score [p = 0.7570]. Table 2 provides the values for 
demographics and clinical characteristics of study patients. 
 Patients were excluded from IV-TXA use due to their comorbidities as listed in 
Table 2. A majority of the study patients (91%) had at least one of the listed 
comorbidities ranging up to 7 comorbidities. 9% of all study patients were not 
administered IV-TXA based on the clinical judgement of the anesthesiologist or surgeon, 
outside of the comorbidities listed on Table 3.  
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 IA-TXA (n = 152) No TXA (n = 119) 
Mean (SD) age, years 69.31 (11.02) 70.12 (9.67) 
Gender, no. (%)   
Female 77 (50.66) 50 (42.02) 
Male 75 (49.34) 69 (57.98) 
Mean (SD)   
BMI, kg/m2 30.88 (6.77) 31.44 (5.96) 
Weight, kg 88.20 (22.25) 90.63 (19.71) 
Length of Stay, days 3.66 (1.99) 3.77 (1.91) 
Type of Anesthesia, no. (%)   
Spinal/Epidural  103 (67.76) 70 (58.82) 
General 49 (32.24) 49 (41.18) 
ASA Score, no. (%)   
ASA I/II 19 (12.50) 19 (15.97) 
ASA III/IV 133 (87.50) 100 (84.03) 
Surgery, no. (%)   
TKA 83 (54.61) 72 (60.50) 
Anterior THA 37 (24.34) 20 (16.81) 
Posterior THA 32 (21.05) 27 (22.69) 
Table 2. Demographic and Clinical Characteristics: Patient demographic and clinical characteristics by 
treatment and control group including all surgery types 
 IA-TXA (n = 152) No TXA (n = 119) 
History of DVT or PE within prior 12 
months 
25 (16.45) 34 (28.57) 
Mitral or aortic valve replacement with 
additional risk factor for stroke 
7 (4.61) 5 (4.20) 
History of cancer 40 (26.32) 18 (15.13) 
Inherited thrombophilia 3 (1.97) 6 (5.04) 
Acquired thrombophilia 10 (6.58) 4 (3.36) 
Cardiac stents 42 (27.63) 37 (31.09) 
History of stroke or TIA 22 (14.47) 14 (11.76) 
Serum creatinine > 2.8 mg/dL 1 (0.66) 0 (0.00) 
Allergy to TXA 0 (0.00) 0 (0.00) 
CABG 8 (5.26) 10 (8.40) 
Taking Plavix or equivalent 4 (2.63) 15 (12.61) 
CAD 19 (12.50) 40 (33.61) 
Atrial fibrillation 18 (11.84) 22 (18.49) 
Carotid stenosis 0 (0.00) 5 (4.20) 
Table 3. Preoperative Comorbidities (%): Comorbidities assessed for the study by treatment and control 
groups. All comorbidities listed are known indicators for future VTE events. All surgery types were 
included. 
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Estimated Blood Loss  
 Between treatment and control groups, no statistically significant difference was 
found regarding mean EBL on POD 1 [p = 0.3127]; however, the type of surgery was 
shown to have a statistically significant effect. TKA patients who were not administered 
TXA on average had 305.84 units more blood loss than TKA patients who were 
administered IA-TXA [p = 0.004]. The effect did not hold when comparing treatment and 
control groups in both anterior and posterior THA patients, respectively. Table 4 displays 
EBL on POD 1 by procedure type between treatment and control groups. 
 
 IA-TXA (n = 152) No TXA (n = 119) P 
TKA 1133.32 1439.16 0.0039 
Anterior THA 1492.77 1362.15 0.9449 
Posterior THA 1282.61 1324.67 0.9996 
Table 4. Estimated Blood Loss on POD 1: Calculated EBL before administration of VTE medication on 
POD 1 by treatment and control group, and surgery type. EBL was calculated in mL. P values < 0.05 were 
considered significant.   
 
When looking at the blood loss throughout the entire hospitalization, a statistically 
significant difference in estimated blood loss was seen between treatment and control 
group. Specifically, patients who were not administered TXA had, on average, 124.64 
units more in blood loss than in patients who were administered IA-TXA [p = 0.003]. 
This effect did not hold when comparing treatment and control groups by type of surgery. 
Analysis for EBL post medication was not populated by the SAS system because the 
interaction between the two variables, EBL post medication and surgery type, was not 
significant. 
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The age at surgery and gender were significantly associated with the EBL: for 
every year increase in age, there was a decrease in blood loss by 12.2 units on POD 1 
after adjusted by other covariates (administration of IA-TXA, gender, type of surgery, 
surgeon, type of anesthesia) [p < 0.0001]. Females, on average, had 237.3 units less 
blood loss on POD 1 than males after adjusted by other covariates (administration of IA-
TXA, gender, type of surgery, surgeon, type of anesthesia) [p = 0.0003]. The interaction 
between gender and blood loss remained throughout the entire hospitalization, with 
females, on average, having 255.3 units less blood loss than males after adjusted by other 
covariates [p < 0.0001].   
 
Change in Hemoglobin and Hematocrit  
 No statistically significant difference existed in hemoglobin levels over time 
between treatment and control groups; however, patients that were not administered TXA 
showed, on average, a lower level of hematocrit than patients that were administered IA-
TXA by 0.9 units [p = 0.041]. Table 5 shows the difference in average hematocrit levels 
over the entire hospitalization between treatment and control groups. 
 The age at surgery and gender were significantly associated with level of 
hemoglobin and hematocrit after adjusted by other covariates. For every year increase in 
age, there was a decrease in hemoglobin level by 0.03 units and a decrease in hematocrit 
level by 0.06 units [p < 0.001, p = 0.003, respectively]. Females had 1 unit of hemoglobin 
and 2.6 units of hematocrit lower than that of males after adjusted by other covariates [p 
< 0.001].  
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Transfusions  
33 patients (12%) required a post-operative allogeneic transfusion. Specifically, 
9% of patients who were administered IA-TXA required a transfusion, while 16% of 
patients who were not administered TXA required a transfusion. There was no 
statistically significant difference in the number of patients requiring transfusions 
between treatment and control groups. Table 5 displays the number of patients requiring a 
transfusion by procedure type between treatment and control groups. 
 IA-TXA (n = 152) No TXA (n = 119) P 
Patients requiring transfusion, no. (%) 14 (9.21) 19 (15.97) 0.0915 
Difference in mean hematocrit, units --- -0.8759 0.0409 
Table 5. Transfusion, Hematocrit: Number of patients requiring postoperative transfusions and the 
difference in mean hematocrit between treatment and control groups (negative sign indicates less than the 
comparison group). P values less than 0.05 were considered significant.  
Thromboembolic Events  
5 patients (1.85%) were found to have a symptomatic thromboembolic event 
within 30 days after the day of surgery. 4 patients (1.48%) were found to have 1 DVT 
each, while 1 patient (.37%) was found to have both a DVT and a CVA (cerebrovascular 
accident)1. 3 patients (1.97% of TXA group), including the patient with 2 postoperative 
VTE events, were part of the treatment group (IA-TXA), while 2 patients (1.68% of 
controls) were part of the control group (no TXA). No patients were found to have a PE. 
No statistically significant difference was found in the number of patients that had a 
thromboembolic event [p = 0.915]. Table 6 displays the number of patients found to have 
a thromboembolic event between treatment and control group.     
1 This patient was found to have an undiagnosed Patent Foramen Ovale (PFO), which can allow for a 
crossing of venous to arterial blood in the heart. Therefore, although a CVA is arterial in nature, it was 
included in our venous thromboembolism events because of its possible venous origin (Yee-Ping, Homma, 
2016). 
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Infections  
 14 patients (5.17%) were found to have a surgical site wound infection. 6 of these 
patients were not administered TXA (5.04% of control group), while 8 of these patients 
were administered IA-TXA (5.26% of treatment group). All of these infections were 
characterized as superficial infections; no patients showed any presence of a deep wound 
infection. There was no statistically significant difference in the number of patients who 
had infections between treatment and control groups [p = 0.935]. Table 6 includes the 
number of patients who were found to have infections between treatment and control 
groups. 
Table 6. Safety outcomes: Number of VTE events and infections that occurred in patients postoperatively. 
All infections were found to be superficial infections. P values less than 0.05 were considered significant.   
  
 IA-TXA (n = 152) No TXA (n = 119) P 
VTE events (DVT, PE), no. (%) 3 (1.97) 2 (1.68) 1.000 
Infections (superficial), no. (%) 8 (5.26) 6 (5.04) 0.935 
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DISCUSSION 
 
 In this retrospective chart review of TKA, anterior THA, and posterior THA 
patients, topical administration of TXA reduced perioperative blood loss on POD 1 in 
TKA [p = 0.0039] but not in THA [anterior THA: p = 0.9449; posterior THA: p = 
0.9996]. Following the entire hospitalization, patients who were administered IA-TXA 
had significantly less blood loss than control patients [p = 0.0275]. In addition, patients 
who were administered IA-TXA had a smaller decrease in hematocrit than control 
patients [p = 0.0409].  
  
Efficacy of TXA in TKA 
 Our results are consistent with other studies describing the efficacy and safety of 
IA-TXA in TKA. Wong et. al (2010) showed a statistically significant decrease in total 
blood loss from IA-TXA administered patients compared to placebo administered 
patients [p = 0.0001]. Martin et. al (2014) showed that after both THA and TKA, there is 
a statistically significant difference in maximum decline of postoperative hemoglobin 
between IA-TXA administered patients and placebo administered patients. Specifically, 
there was a greater hemoglobin decline in placebo administered patients than in IA-TXA 
administered patients [p = 0.013] (Martin et. al, 2014). Finally, Georgiadis et. al (2013) 
found that there was a statistically significant decrease in perioperative blood loss when 
patients were administered IA-TXA compared to patients who were administered a 
placebo [p < 0.001].  
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Lack of efficacy of TXA in THA 
On the other hand, IA-TXA was not shown to be efficacious in reducing early 
EBL (day of surgery to POD1) for study patients that underwent THA (posterior and 
anterior approaches). This contradicts the conclusions made from a variety of existing 
studies looking at IA-TXA in THA (summarized in Table 7); however, multiple factors 
can be considered to explain this discrepancy. The first factor involves the volume that 
TXA is instilled in. Our current departmental protocol for IA-TXA calls for 2 grams of 
TXA instilled in 50mL of normal saline. Since THA involves a larger surgical site than in 
TKA, more volume may be required to reach all relevant parts within the joint and induce 
efficacy for TXA in the hip. In fact, other studies have shown efficacy of IA-TXA 
instilled in volumes of up to 150mL (Yue et. al, 2014).  
The second factor involves how and when TXA is administered during the 
surgery. Our current departmental protocol calls for TXA to be irrigated in the joint 
through a bulb syringe before closing and left undisturbed for 5 minutes before 
suctioning out any excess solution. This is one of many different types of administrations 
of IA-TXA (summarized in Table 6). In a prospective study of IA-TXA in THA and 
TKA, Konig et. al (2013) describes instilling TXA at 3 different points during the 
surgery. A similar process has been followed by the study conducted by Yue et. al 
(2014). In this procedure, TXA is poured over the acetabulum and femoral canal after 
their respective preparations, and finally over the completely inserted hip components 
(Konig et. al, 2013). By spreading the administration of IA-TXA throughout the entire 
surgery, there is more timely and direct contact with the bleeding areas. In contrast, TXA 
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may not have the same direct contact to the bleeding tissue when waiting to administer 
until all components are affixed. 
The third factor involves the dosage of TXA used. During the study period, the 
departmental protocol used 2 grams of TXA, while other studies have used doses of up to 
3 grams of TXA. The evidence for using higher doses of TXA is mixed, at best. While 
some studies, such as a prospective randomized trial conducted by Yue et. al (2014), 
show that higher doses of TXA (i.e. 3 grams) provides safety and efficacy after THA, 
other studies, such as the meta-analysis endorsed by many professional organizations (i.e. 
American Association of Hip and Knee Surgeons, American Society of Regional 
Anesthesia and Pain Medicine, American Academy of Orthopedic Surgeon), show that 
there is no statistically significant difference in outcome measures that predict efficacy 
between using low dose TXA (≤ 1.5 g) and high dose TXA (> 1.5 g) (Filingham et. al, 
2018). There is also still concern from clinicians that higher doses of TXA will lead to 
greater systemic absorption, putting the patient at a greater risk for having a 
thromboembolic event. Following this concern, TXA usage has generally been 
contraindicated in patients with a significant history for VTE events or acquired/inherited 
thrombophilia. 
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Author Dosage Administration Outcomes 
Konig et. 
al (2013) 
3 g in 
100 mL 
1. Bathe acetabulum with 
20 mL of TXA       
2. Pour 20 mL of TXA in 
femoral canal                 
3. Pour final 60 mL into the 
wound (leave in wound) 
1. Lowest Hgb postop: 9.4 ± 1.4 
(Control) vs. 10.5 ± 1.4 (TXA) [p < .01]                                                                                      
2. ΔHgb: 4.7 ± 1.3 (Control) vs. 3.7 ± 
1.2 (TXA) [p < .01]                                                                           
3. Transfusion rates: 15% (Control) vs. 
1% (TXA) [p < .01] (Hgb < 8)                                                                                             
4. Total Blood Loss: 1729 ± 552 mL 
(Control) vs. 1384 ± 456 mL (TXA) [p < 
.01] 
Yue et. al 
(2014) 
3 g in 
150 mL 
1. Place 50 mL gauze of 
TXA into acetabulum                          
2. Place 50 mL gauze of 
TXA into femoral canal                                                    
3. Inject 50 mL of TXA 
into hip joint 
1. Transfusion Rate: 22.4% (Control) vs. 
5.7% (TXA) [p = .021]                                                                                                                  
2. Complications: 1 DVT (TXA) 
3. Total Blood Loss: 1255.5 ± 193.5 mL 
(Control) vs. 945.5 ± 331.7 mL (TXA) 
[p < .001]                                                                                                                                                                                            
4. Drain Blood Loss: 269.9 ± 109.0 mL 
(control) vs. 217.5 ± 89.9 mL (TXA)                                                                                         
5. ΔHbg/Hct: significantly lower in IA-
TXA group than control group 
Martin et. 
al (2013) 
2 g in 
100 mL 
After final washout, wound 
is bathed in 100 mL of 
TXA for 2 minutes and 
suctioned after 
1. ΔHgb: 4.71 g/L (control) vs. 4.10 g/L 
(TXA) [p = 0.013]                                     
2. Transfusion rate: 20% (control) vs. 
14.3% (TXA) [p = 0.423] 
Zhang et. 
al (2016) 
1 g in 
100 mL 
After closure, 100 mL of 
TXA injected via drainage 
tube 
1. Hgb POD 1: 91 ± 15 (IA-TXA) vs. 84 
± 14.0 (control) [p < 0.01]                                                               
2. Hct POD 1: 35.8 ± 4.2 (IA-TXA) vs. 
29.7 ± 3.4 (control) [p < 0.01]                                                                     
3. Hgb POD 3: 89 ± 11 (IA-TXA) vs. 82 
± 13 (control) [p < 0.01]                                                                  
4. Hct POD3: 33.4 ± 3.2 (IA-TXA) vs. 
30.7 ± 3.6 (control) [p < 0.01] 
5. Postop. drainage volume: 300 mL (IA-
TXA) vs. 500 mL (control) [p < 0.05]                                          
6. Total Blood Loss: 900 mL (IA-TXA) 
vs. 1100 mL (control) [p < 0.05]  
Alshryda 
et. al 
(2013) 
1 g in 
50 mL 
50 mL of TXA sprayed into 
wound before closing 
1. Total Blood Loss: 1981 mL (control) 
vs. 1617 mL (IA-TXA) [p= 0.059]                                                                         
2. Hbg POD2: 9.78 g/dL (control) vs. 
10.62 g/dL (IA-TXA) [p < 0.0001]                                                                              
3. Hct POD2: .29 (control) vs. .31 (IA-
TXA) [p < 0.0001]                                                                                                  
4. Transfusion: 32.1% (control) vs. 
12.5% (IA-TXA) [p = 0.004] 
Table 7. Summary of selected IA-TXA studies in THA: Summary of sequential steps taken in the 
administration of IA-TXA, and the significant primary outcomes that were measured. Included is the 
dosage of TXA used, the volume it was instilled in, and the publication authors/year. 
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Safety of TXA in TKA and THA  
As mentioned previously, clinicians have shown greater interest in minimizing 
systemic absorption of TXA by utilizing the intra-articular application of TXA. 
Stemming from this caution, a majority of high-level studies analyzing IA-TXA use in 
THA and TKA have not included this subset of patients with these significant 
comorbidities. In fact, in the recent meta-analysis by Filingham et. al (2018), it was 
concluded that there is still a lack of high level evidence from studies that involve 
patients with a history of VTE, MI, CVA, TIA, and/or vascular stent placement. Due to 
the retrospective nature of our study, we were able to include these high risk patients in 
the analysis, which showed that there was no statistically significant difference in the rate 
of VTE events or infections between treatment and control groups. However, although 
not statistically significant, there was a slightly higher number of VTE events and 
infections in the treatment group compared to control group. This illustrates further 
research is needed regarding the inclusion of patients at high-risk of VTE for IA-TXA 
administration. 
 
Gender and age 
There was a decrease in hemoglobin level with every increase in age by year. This 
decrease in hemoglobin may be explained by older aged individuals having decreased 
hematopoietic activity. In fact, one study found that the bone marrow cellularity 
decreases up to 50% in people that are older than 60 years of age (Mahlknecht and 
Kaiser, 2010). This suggests that peripheral blood counts, including the patient’s 
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hematocrit levels, would be reduced in older aged individuals. Additionally, we found 
that hemoglobin and hematocrit levels varied significantly between males and females. In 
the previously mentioned study, males were shown to have a decreased amount of 
erythroid and myeloid progenitors compared to that of females, suggesting that males 
would have a decreased peripheral blood count compared to that of females (Mahlknecht 
and Kaiser, 2010); however, the results of our study show the opposite: females had a 
decreased amount of hemoglobin and hematocrit than that of males. This discrepancy 
indicates that further research is needed in describing blood count differences between 
genders perioperatively. 
 
Limitations   
This study was a retrospective chart review, limiting the applicability of its 
results; however, the retrospective nature allowed us to include all subsets of patients in 
our analysis. These results would offer direction as to how to approach future prospective 
studies. Additionally, there were some parameters measured in this study that were not 
effectively standardized between each patient. This included the time points between 
surgery and VTE medication administration, and between VTE medication 
administration and discharge. The slight variability in time may have influenced when the 
lowest hematocrit level used in calculating the estimated blood loss was collected, and 
may therefore have influenced the primary endpoints of the study. 
 Finally, this study mainly captured clinical data from the patient’s time within the 
hospital (exceptions include preoperative blood counts, and postoperative complications 
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at 30 and 90 days after surgery). As perioperative blood loss can influence and effect a 
patient’s recovery after discharge from the hospital, further investigation into the patient 
within the outpatient setting is needed. 
 
Future research 
 With the results of this retrospective study, there is a more clear direction as to 
where to place our attention. First of all, with the lack of efficacy for IA-TXA in THA, 
certain factors can be explored. Specifically, the timing and placement, the dosage, and 
the volume instilled need to be further studied as factors that can influence the efficacy of 
IA-TXA administration in THA. When looking to the current literature for IA-TXA 
usage in THA, there is a lack of agreement and standardization as to the optimal 
administration of IA-TXA. This indicates the need for a study that uses a standardized 
method across all patients to compare specific factors that influence IA-TXA efficacy in 
THA patients.  
With the lack of a statistically significant difference in VTE and infection rates, 
our safety outcomes for IA-TXA in THA and TKA indicate an opportunity to develop 
higher level studies that include patients at higher-risk for VTE and infection. 
Additionally, further study and discussion can be made regarding the role of gender and 
age in peripheral blood counts found in the perioperative period.  
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APPENDIX I: Departmental Protocol for IA-TXA Administration in THA & TKA 
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APPENDIX II: Departmental VTE Prophylaxis Protocol in THA and TKA 
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